The global Artificial Intelligence (AI) in precision medicine market is expected to experience significant growth, reaching $3.92 billion by 2030, up from $0.78 billion in 2024, at a Compound Annual Growth Rate (CAGR) of 30.7%.
This growth is driven by advancements in genomic research, increased investments in R&D, and a growing demand for personalized medicine and targeted therapies. The increasing availability of genomic data and advancements in genomic research are propelling the adoption of AI in precision medicine.
AI is being used in various applications, including drug discovery and development, diagnostics and screening, and therapeutics. In drug discovery and development, AI is accelerating the process by analyzing large amounts of data and identifying potential drug targets. AI-powered diagnostics and screening tools are improving disease detection and diagnosis, while AI is also being used to develop personalized treatment plans and targeted therapies.
Key players in the market include NVIDIA Corporation, Google, Inc., Microsoft, IBM, and Exscientia. These companies are investing heavily in R&D to develop innovative AI-powered precision medicine solutions. The market is expected to continue growing as AI technology advances and becomes more widely adopted in the healthcare industry.
